Autor: |
Ryosuke Maeoka, Yukiteru Ouji, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Shohei Yokoyama, Shuichi Yamada, Fumihiko Nishimura, Ichiro Nakagawa, Young-Soo Park, Masahide Yoshikawa, Hiroyuki Nakase |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115296- (2023) |
Druh dokumentu: |
article |
ISSN: |
0753-3322 |
DOI: |
10.1016/j.biopha.2023.115296 |
Popis: |
Background: Glioblastoma is a type of intracranial malignancy. Shikonin, a Chinese traditional medicine, has been shown to have anti-tumor efficacy toward human glioblastoma cells in vitro. However, shikonin cannot easily cross the blood–brain barrier. To address this issue, we evaluated the anti-tumor effects of direct intracranial infusion of shikonin in in vivo orthotopic syngeneic murine glioblastoma models using C57BL/6 mice. Materials and methods: The cytotoxic effects of shikonin against murine glioblastoma cells, SB28 and CT-2A, were reported resistance to temozolomide, were evaluated using an allophycocyanin-conjugated annexin V and propidium iodide assay with flow cytometry. Impedance-based real-time cell analysis (RTCA) was used to analyze the inhibitory effects of shikonin on growth and proliferation. To evaluate the anti-tumor activity of shikonin in vivo, we used orthotopic syngeneic murine glioblastoma models with SB28 and CT-2A cells. Results: In flow cytometry-based cytotoxic assays, shikonin induced apoptosis. RTCA indicated that shikonin decreased the cell index of murine glioblastoma cells, SB28 and CT-2A, in a dose-dependent manner (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|